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Abstract  1 
Background & Aims: Hepatic innate immune control of viral infections has largely 2 
been attributed to Kupffer cells, the liver macrophages. However, also hepatocytes, 3 
the parenchymal cells of the liver, possess potent immunological functions in 4 
addition to their known metabolic functions. Owing to their abundance in the liver and 5 
known immunological functions, we aimed to investigate the direct anti-viral 6 
mechanisms employed by hepatocytes. 7 
Methods: Using lymphocytic choriomeningitis virus (LCMV) as a model of liver 8 
infection, we first assessed the role of myeloid cells by depletion prior to infection. 9 
We investigated the role of hepatocyte-intrinsic innate immune signaling by infecting 10 
mice lacking canonical NF-κB signaling (IKKβ∆Hep) specifically in hepatocytes. In 11 
addition, mice lacking hepatocyte-specific interferon-α/β signaling-(IFNAR∆Hep), or 12 
interferon-α/β signaling in myeloid cells-(IFNAR∆Myel) were infected. 13 
Results: Here, we demonstrate that LCMV activates NF-κB signaling in 14 
hepatocytes. LCMV-triggered NF-κB activation in hepatocytes did not depend on 15 
Kupffer cells or TNFR1- but rather on TLR-signaling. LCMV-infected IKKβ∆Hep livers 16 
displayed strongly elevated viral titers due to LCMV accumulation within 17 
hepatocytes, reduced interferon-stimulated gene (ISG) expression, delayed 18 
intrahepatic immune cell influx and delayed intrahepatic LCMV-specific CD8+ T-cell 19 
responses. Notably, viral clearance and ISG expression were also reduced in LCMV-20 
infected primary hepatocytes lacking IKKβ, demonstrating a hepatocyte-intrinsic 21 
effect. Similar to livers of IKKβ∆Hep mice, enhanced hepatocytic LCMV accumulation 22 
was observed in livers of IFNAR∆Hep, whereas IFNAR∆Myel mice were able to control 23 
LCMV-infection. Hepatocytic NF-κB signaling was also required for efficient ISG 24 
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induction in HDV-infected dHepaRG cells and interferon-α/β-mediated inhibition of 1 
HBV replication in vitro.  2 
Conclusions: Together, these data show that hepatocyte-intrinsic NF-κB is a vital 3 
amplifier of interferon-α/β signaling pivotal for early, strong ISG responses, influx of 4 
immune cells and hepatic viral clearance. 5 
 6 
Lay summary 7 
Innate immune cells have been ascribed a primary role in controlling viral-clearance 8 
upon hepatic infections. We identified a novel dual role for NF-κB in infected 9 
hepatocytes crucial for maximizing interferon responses and initiating adaptive 10 
immunity, thereby efficiently controlling hepatic virus replication.  11 
12 
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Highlights 1 
• LCMV infection activates NF-κB signaling in hepatocytes 2 
• Macrophages, TNFR1 signaling do not induce LCMV-driven hepatocyte NF-3 
κB-activation  4 
• IKKβ∆Hep mice display increased viral infection/replication and lower ISG 5 
induction 6 
• IFNAR∆Hep mice recapitulate aberrant virus replication as observed in IKKβ∆Hep 7 
mice 8 
• NF-κB signaling is required for efficient ISG induction in HBV-/HDV-infected 9 
HepaRG 10 
11 
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Introduction 1 
The liver is constantly exposed to pathogens coming from the gut via the hepatic 2 
portal vein (1). Owing to this unique anatomical position, the liver not only serves as 3 
a metabolic organ but also plays a central role in supporting innate and local 4 
adaptive immunity (2). While maintaining immune tolerance, the liver continuously 5 
removes a large and diverse spectrum of pathogens from the circulation, assuring 6 
organ protection (3). The liver has the largest population of resident macrophages in 7 
the whole body (3). Consequently, a sub-lethal bacterial inoculum in mice depleted 8 
of liver resident macrophages (Kupffer cells; KCs) leads to increased bacterial load, 9 
dissemination and death (4, 5), suggesting that the liver plays a non-redundant role 10 
in conferring immunity to infections.  11 
Hepatocytes are parenchymal cells of the liver encompassing ~80% of the entire 12 
liver cell mass. In addition to being centrally involved in metabolic functions, plasma 13 
protein expression and detoxification, hepatocytes are known to possess potent 14 
immunological functions (6, 7). Several pathogen recognition receptors (PRRs) are 15 
strongly expressed by hepatocytes (8). Upon encountering pathogen-associated 16 
molecular patterns (PAMPs), hepatocytes readily secrete inflammatory cytokines, 17 
which help control the spread and growth of pathogens (9). Owing to their 18 
abundance in the liver and known immune functions, we aimed to investigate the 19 
direct/indirect anti-viral mechanisms employed by hepatocytes. 20 
Efficient clearance of a viral infection requires early detection of viral DNA or RNA by 21 
pattern recognition receptors (PRRs) and induction of interferon responses, which 22 
serves as the first line of defense. Interferons act by binding to type I interferon 23 
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receptors (IFNARs) on the cell surface initiating a signaling cascade by the JAK-1 
STAT pathway leading to the upregulation of interferon stimulated genes (ISGs). 2 
Induction of ISG responses creates an effective cell-intrinsic antiviral state, which 3 
restricts the replication of most viruses at an early stage (10).  4 
Non-cytopathic lymphocytic choriomeningitis virus (LCMV-WE) is a negative-sense 5 
single-stranded RNA virus belonging to the Arenaviridae family (11, 12). The 6 
replication intermediates of this virus involve formation of dsRNA and 5′-PPP 7 
structures, which are recognized by RIG-I and MDA5 activating IRF3 and NF-kB-8 
mediated interferon responses (13, 14). While the downstream signaling from the 9 
receptors of these stimuli might vary, in most of the cases, they all converge on the 10 
activation of IKK (IκB kinase) complex. The IKK complex consists of two catalytic 11 
kinase subunits, IKKα and IKKβ with intrinsic kinase activities and a regulatory 12 
subunit, IKKγ, also known as NF-κB essential modulator (NEMO) with helix-loop 13 
helix and leucine-zipper motifs that mediate protein-protein interactions (15, 16). In 14 
the inactive state p50:p65 dimers are held in the cytoplasm in association with the 15 
inhibitors of kappaB (IκB) proteins which mask the nuclear localization signal. The 16 
activated IKK complex phosphorylates IκB proteins at amino terminal serine residues 17 
and marks them for ubiquitin-mediated proteasomal degradation, upon which NF-κB 18 
dimers translocate to the nucleus to bind DNA and enable gene transcription.  19 
NF-κB is activated by multiple viruses such as Human Immunodeficiency Virus, 20 
Hepatitis C Virus, Rio Bravo Virus and influenza to enhance viral replication or 21 
escape virus-induced apoptosis (17). Some viruses, such as VACV, encode proteins 22 
with ankyrin repeats mimicking IκB family proteins thereby inhibiting NF-κB signaling 23 
and subsequent immune responses (18). Furthermore, IKKβ is essential for 24 
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induction of type I IFN and other inflammatory cytokines in response to a viral 1 
infection (19).  2 
To determine the relative contribution of hepatocytes to viral clearance in the liver, 3 
we used a mouse model in which the essential upstream kinase in canonical NF-κB 4 
signaling, IKKβ, was selectively deleted in hepatocytes by Cre recombinase-5 
mediated excision under the control of the albumin promoter - IKKβ∆Hep mice (20-23). 6 
These IKKβ∆Hep mice were infected systemically with LCMV-WE strain. LCMV-WE 7 
leads to an acute infection that is usually cleared within 2-3 weeks by virus-specific 8 
CD8+ T cells. Intravenous infection in mice leads to infection of multiple visceral 9 
organs such as lung, kidney, spleen, and liver (24, 25). Following a systemic 10 
infection with LCMV in IKKβ∆Hep mice, we analyzed the dynamics of viral replication 11 
and clearance with a focus on the relative contribution of hepatocytes compared to 12 
IFNAR∆Hep, IFNAR∆Myel, and wild-type (WT) livers. Our findings were corroborated in 13 
differentiated HepaRG cells lacking IKKβ either treated with IFN-α/TNFα or infected 14 
with HDV. Our results highlight a central role of hepatocyte-intrinsic NF-κB signaling 15 
in supporting innate and adaptive immune responses to systemic viral infections. 16 
17 
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Materials and Methods 1 
Animals and infections 2 
Alb-Cre transgenic mice expressing Cre recombinase from the hepatocyte-specific 3 
albumin promoter were crossed with IKKβfl/fl mice and IFNARfl/fl mice to generate 4 
IKKβ∆Hep mice and IFNAR∆Hep mice (20-22). LysM-Cre mice expressing Cre in 5 
myeloid cells due to a targeted insertion of the cre cDNA into their endogenous M 6 
lysozyme locus were crossed with IFNARfl/fl mice to generate IFNAR∆Myel mice (26). 7 
To control the effects of Cre-induced cytotoxicity, histology was performed on livers 8 
obtained from C57BL/6 (WT), Alb-Cre, and IKKβ∆hep mice. No phenotypic differences 9 
were observed between WT and Alb-Cre mice. A total of 237 mice, of both male and 10 
female gender, were used in the experiments aged between 4 to 5 months. Each 11 
experiment has been performed with 3 to 6 mice. Mice used for experiments were 12 
maintained in single ventilated cages and under specific pathogen-free conditions. 13 
All mice used were of a C57BL/6/J genetic background. LCMV-WE was originally 14 
obtained from Rolf Zinkernagel (University Hospital Zurich (USZ), Switzerland) and 15 
propagated by infection of L929 fibroblast cells. Infection experiments were 16 
performed in Zurich under the licenses ZH 200/2006 and ZH 69/2012 as approved 17 
from the cantonal veterinary office of Zürich. Infection doses were given as indicated 18 
in each experiment, intravenously. At least 3-6 mice were used in each experimental 19 
group. 20 
Clodronate treatment 21 
Macrophages were depleted by injecting 200 µl (~1 mg) of Clodronate-encapsulated 22 
liposomes (LIPOSOMA research, Cat no: CP-005-005 – 5 mg/ml formulation) 23 
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through the i.v. route in accordance with manufacturer’s directions for administration 1 
(0.1 ml/10 g body mass). 200 µl of PBS-encapsulated liposomes were used as 2 
control. On day 2 post clodronate treatments, infections were carried out using 3 
LCMV (27).  4 
LCMV nuclear protein (NP) immunofluorescence  5 
5 µm liver cryo-sections on glass coverslips (ThermoFisher) from LCMV-infected 6 
mice were fixed in ice-cold 100% acetone for 10 min. Sections were then blocked for 7 
15 min in 2% fetal calf serum (FCS; Hyclone) in PBS. Sections were then incubated 8 
overnight at 4° C in anti-LCMV NP supernatant (clon e VL4) (24) diluted 1:4 in 2% 9 
FCS in PBS. Sections were washed in PBS and incubated for 1 h in 2 µg/ml 10 
AlexaFluor 488-conjugated goat anti-rat secondary antibody (Invitrogen) containing 11 
1:10,000 DAPI in 2% FCS in PBS. Sections were then washed in PBS and mounted 12 
with fluorescent mounting medium (Dako), cover-slipped, and imaged using an 13 
Olympus BX53F fluorescent microscope or with a confocal Zeiss LSM 710 ConfoCor 14 
3. 15 
RelA immunofluorescence 16 
5 µm liver cryo-sections on glass coverslips from LCMV-infected mice were fixed in 17 
4% formalin for 10 min, washed in PBS for 2 min, and then washed for 10 min in 18 
PBS with 0.1% Tween 20 (PBST). Sections were then blocked for 1 h in 5% FCS 19 
and 0.25% Triton X-100 in PBS. Sections were then incubated at 4°C overnight in 20 
anti-RelA (NeoMarkers # RB-1638-P0) diluted 1:100 in 1% bovine serum albumin 21 
(BSA), 0.25% Triton-X 100 in PBS. Sections were then washed in PBS for 2 min., 22 
followed by PBST for 2 min, and incubated for 1 h in 4 µg/ml AlexaFluor 488-23 
Namineni, et al. 
 
11 
 
conjugated goat anti-rabbit secondary antibody containing 1:10,000 DAPI in 1% BSA 1 
and 0.25% Triton-X 100 in PBS. Sections were then washed in PBS followed by 1x 2 
PBST, mounted with fluorescent mounting medium, cover-slipped, and imaged using 3 
an Olympus BX53F fluorescent microscope. 4 
CD169 immunofluorescence 5 
Histological analyses were performed on snap-frozen tissue as described previously 6 
(28). In brief, slides were fixed with Acetone for 10 min, incubated for 15 min in PBS 7 
and blocked with 2% FCS for 15 min. Sections were stained with rat anti-LCMV-NP 8 
antibody (clone VL4) and developed with FITC-anti-Rat-IgG1/2a (BD Pharmingen 9 
Clone: G28-5, Cat: 553881). Additionally, CD169-PE (R&D Systems, 5610P) and 10 
F4/80-APC (eBiosciences, 17-4801) were used to visualize macrophage subsets. 11 
Pictures of slides were taken with Keyence BZ-9000.  12 
Clec4F immunofluorescence 13 
Liver tissue samples were fixed in 4% paraformaldehyde for 5 days at room 14 
temperature and embedded in paraffin and ~2 µm tissue sections were made using 15 
a microtome. The sections were later de-paraffinized, rehydrated and boiled at 16 
100°C with EDTA to facilitate antigen retrieval. An tigen retrieval was performed with 17 
96°C sodium citrate buffer. Slides were washed with  TBS-Tween. Primary antibody, 18 
purchased from R&D systems (1:2000), and secondary antibody, purchased from 19 
Jackson ImmunoResearch (1:250), were incubated sequentially for 1 h at RT in a 20 
humid chambers. Slides were mounted in DAPI Fluoromount-G® and kept in the 21 
dark at 4°C. Slides were imaged with a confocal Zei ss LSM 710 ConfoCor 3. 22 
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RNA isolation and quantitative PCR analysis  1 
Total RNA was isolated from approximately 20 mg of liver tissue lysed in RLT buffer 2 
from an RNeasy mini kit (Qiagen) using a gentleMACS™ Dissociator (Miltenyi 3 
Biotec). Spectrophotometric measurement of the quality and quantity of isolated 4 
RNA was done using Nanodrop (ThermoFisher). 1 µg of RNA was reverse 5 
transcribed to cDNA using Quantitect Reverse Transcription Kit (Qiagen) following 6 
the instructions from the manufacturer. Relative mRNA expression was analyzed in 7 
duplicates on 384-well PCR plates (ThermoFisher) using FastStart Universal SYBR 8 
Green Master (Rox) and the qPCR was run on 7900 HT qRT-PCR system (Applied 9 
Biosystems). Relative mRNA levels were calculated through ∆∆CT relative 10 
quantification method and the obtained values were normalized to housekeeping 11 
genes albumin (for liver), β-actin and GAPDH. For HBV- or HDV-infected HepaRGs, 12 
total RNA and total DNA were respectively extracted from cells with the NucleoSpin 13 
RNA II kit and Nucleospin® tissue kit according to the manufacturer’s (Macherey-14 
Nagel) instructions. RNA reverse transcription was performed using the Superscript 15 
III RT (Life Technologies). Quantitative PCR were performed specific primers and 16 
normalized to PRP housekeeping gene as previously described (29, 30). TNFα- and 17 
IFN-α-treated HepaRGs, were washed once with PBS, lysed in RLT buffer (Qiagen), 18 
passed through a QiaShredder column (Qiagen), and RNA was extracted using the 19 
RNeasy Mini Kit (Qiagen). Reverse transcription was performed with the Quantitect 20 
Reverse Transcription Kit using 500 ng total RNA and subsequent qPCR analysis 21 
was done by using the FastStart Universal SYBR Green Master (Rox) (Roche). 22 
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Immunohistological stainings  1 
Liver tissue samples were fixed in 4% paraformaldehyde for 5 days at room 2 
temperature and embedded in paraffin and ~2 µm tissue sections were made using 3 
a microtome. The sections were later de-paraffinized, rehydrated and boiled at 4 
100°C with EDTA to facilitate antigen retrieval. IH C staining was performed with a 5 
Leica automated BOND-MAX staining platform using Bond Polymer Refine Detection 6 
kit (Leica, Catalog #DS9800). Staining was performed using antibodies purchased 7 
from Cell Signaling for pSTAT1-pY701 (1:100 dilution), and pSTAT3 (1:100 dilution), 8 
from ACRIS for STAT2 (1:500 dilution), from Novus Biologicals for MHC-II (1:500 9 
dilution), from Linaris for F4/80 (1:120 dilution), and from abcam for CD68 (1:300 10 
dilution). 11 
pSTAT1, HNF4α and F4/80 sequential staining quantification 12 
Liver tissue samples were cut sequentially and treated and stained as described 13 
above. pSTAT1 positive cells were manually counted in three different view fields per 14 
samples. Based on cells morphology and overlaying with HNF4α positive staining, 15 
pSTAT1 positive cells were divided into two groups: pSTAT1 positive hepatocytes or 16 
pSTAT1 positive non-parenchymal cells (i.e. all other positive cells except 17 
hepatocytes). 18 
CXCL10 and TNFα RNA in situ hybridization (ISH)  19 
RNA in situ hybridization was performed on the liver tissues by following 20 
manufacturer instructions for RNAscope 2.0 FFPE Assay kit –BROWN, purchased 21 
from Advanced Cell Diagnostics. Briefly, 2 µm paraffin sections mounted on glass 22 
slides were boiled at 100°C in EZprep buffer for 20  min followed by a protease 23 
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treatment at 370C for 30 min. Probes specific to mouse CXCL10 or TNFα (Advanced 1 
Cell Diagnostics) were hybridized at 480C for 2 h using HybEZ Hybridization oven 2 
(Advanced Cell Diagnostics) followed by a subsequent series of washing and signal 3 
amplification steps. Mouse specific probe for Ubiquitin C, a common housekeeping 4 
gene is used as a positive control along with a probe for bacterial gene dapB which 5 
served as a negative control. In the end, hybridization signals were detected by DAB 6 
staining followed by counterstaining with hematoxylin. Stained tissues were digitally 7 
scanned using Leica SCN400 scanner (Leica) and hybridization signals were 8 
analyzed at 40x magnification using DIH software (Leica). 9 
DC maturation flow cytometry 10 
Livers and spleens were harvested, perfused with DMEM (Gibco) in the presence of 11 
167 µg/ml of Liberase TM Research Grade (Roche) and 200 µg/ml of DNAse I 12 
(Roche), and incubated 30 min at 37°C. Digestion wa s stopped by adding DMEM 13 
containing 10% FCS (Gibco). Samples were smashed through 70 µm filter and 14 
centrifuged for 5 min at 1500 rpm. Cells were resuspended and incubated for 10 min 15 
at 4°C in FACS buffer (PBS + 1% FCS + 5 mM EDTA) in  presence of 1:50 FC block 16 
(CD16/CD32 monoclonal antibody, Ebioscience). The following antibody panel 17 
(ebioscience) was incubated 30 min at 4 °C: CD8 α-PerCP-eFluor 710, CD11c-PE-18 
Cy7, CD80-FITC, CD86-PE, CD40-APC, MHCII-APC-eFluor 780. Cells were washed 19 
with FACS buffer and centrifuged for 5 min at 1500 rpm. Cells were resupended in 20 
FACS buffer containing DAPI and analyzed in a BD LSRFortessa™ cytometer. 21 
Analysis was then performed on Flow-Jo™. 22 
CXCL10 ELISA 23 
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Approximatively 30 mg of liver was disrupted using 2 mm beads in a protein buffer 1 
(100 mM TRIS pH7.4, 150 nM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X100, 2 
0,5% Sodium deoxycholate, 1 mM PMSF, 1X PIC). Proteins were quantified and 3 
equal concentration of total protein lysate (5 µg/ml) was used to perform the CXCL10 4 
ELISA following manufacture instructions (R&D). 5 
Intracellular cytokine staining  6 
Single-cell suspensions from the liver tissues were obtained by tissue dissection and 7 
grating through a 70 µm cell strainer (Falcon). RBC lysis was performed using BD 8 
Pharm Lyse Buffer (BD Biosciences). ~ 4x106 cells were used for stimulation with 9 
LCMV gp33 peptide or a non-specific peptide at a concentration of 1 µg/ml of peptide 10 
along with Brefeldin A (Golgi-plug; 1 mg/ml). Plates were later incubated for 5 h at 11 
370C. Surface staining was done using CD8α and cells were fixed and permeabilized 12 
(Cytofix/Cytoperm and Perm/Wash Buffer; BD Biosciences), followed by staining 13 
with mAbs to mouse IFN-γ (eBiosciences) and CD8α (eBiosciences). Cells were 14 
fixed on ice in 2% formaldehyde (diluted from Histofix 4%; Carl Roth, Karlsruhe, 15 
Germany) for 1 h followed by fluorocytometric analysis. 16 
Primary hepatocyte isolation 17 
Mice were anesthetized with 120 µl ketamine and xylazine (ketamine 5%, xylazine 2 18 
mg/ml). Livers were perfused with buffer A (10 mM EGTA 1.5 ml + 48.5 ml Hank’s 19 
balanced salt solution) through the portal vein for 5 min. The vena cava was cut as 20 
soon as the perfusion was started, and the perfusion was switched to buffer B 21 
(HBSS with 10 mM Calcium & Collagenase A+D, freshly prepared) and carried out 22 
until the liver turned pale (5-8 min). The liver was later removed and placed in a 100 23 
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µm cell strainer in a petri dish containing William’s E medium. The resulting solution 1 
was passed through a 100 µm (BD Biosciences) cell strainer and collected into a 50 2 
ml falcon filled with 40 ml of buffer C (William's E Medium). The cell suspension was 3 
centrifuged at 50 g (450 rpm) for 2 min. The resulting pellet was washed again twice 4 
in 40 ml of buffer C followed by centrifugation after discarding the supernatant. After 5 
the final wash step, the pellet was re-suspended in 10 ml of buffer C and the viability 6 
of isolated cells was measured using trypan blue at a 1:10 dilution. A viability rate 7 
above 80% was considered appropriate for experimental usage. 0.75 x 106 cells 8 
were plated onto 6-well plates in required quantities and used for the experiments. 9 
HepaRG cell culture and treatments 10 
HepaRG cells were cultured, differentiated, and infected by HBV (MOI 100) and/or 11 
HDV (MOI 10) as previously described (30, 31). HBV inoculum was prepared from 12 
HepAD38 (32) supernatants by polyethylene-glycol-MW-8000 (PEG8000, SIGMA) 13 
precipitation (8% final) as previously described (33). Viral stocks with titers of 14 
superior to 1x1010 vge/ml were tested to be endotoxin free. HDV inoculum was 15 
prepared from transfected HuH7 cells as previously described (30). Viral stocks were 16 
tested to be endotoxin free. rhPEG-IFN-α (Roferon) was purchased Roche and used 17 
at 500 UI/ml. TPCA-1 and ML120B were purchased from SIGMA-Aldrich and used 18 
as IKKβ inhibitors in  Figs. 6 B and D, Figs. S5 D and E at 1 µM and 10 µM, 19 
respectively. HBeAg and HBsAg were detected in the supernatant of HBV-infected 20 
cells using the Autobio kit according to the manufacturer (Autobio Diagnostics Co.). 21 
Evaluation of deletion efficiency and specificity in LysM-Cre IFNARfl/fl and Alb-22 
Cre IFNARfl/fl mice 23 
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KCs and hepatocytes were isolated as previously described (34, 35). Following a 1 
proteinase K digestion, genomic DNA of KCs, splenocytes and hepatocytes were 2 
precipitated O/N at 4°C using 0,3M Na-acetate and e thanol as anti-solvent, washed 3 
twice with ice-cold 70% ethanol and reconstituted in nuclease-free Water. Cre-4 
mediated excision of the loxP flanked genomic region of IFNAR exon 10 was 5 
analyzed by PCR in LysM-Cre IFNARfl/fl and Alb-CreIFNARfl/fl and IFNARfl/fl mice. The 6 
PCR reaction was designed to detect the WT allele at 1264 bp, floxed allele at 1200 7 
bp and the recombined allele at 430 bp with the following primers – dEx10For (5’-8 
GGT TAA GCT CCT TGC TGC TAT CTG G-3’) and dEx10Rev (5’TTG GAG ATG 9 
CAA TCT CGT ACT CAG C-3’). 10 
Generation of differentiated HepaRG∆IKKβ KO cell line  11 
To knock out IKKβ, sgRNAs were chosen based on high scoring and no high scoring 12 
off-targets using CHOPCHOP v2 web tool (36). These sgRNAs were inserted into 13 
pUSEPR (generous gift from Dr. Tscharaganeh, unpublished) based on methods as 14 
described elsewhere (37). Briefly, a sgRNA scaffold fragment was attached to the 5’ 15 
end of a U6 promoter by using overlap extention PCR. In a subsequent PCR 16 
reaction, 20 nt sgRNAs were added to the 5’ end of the sgRNA scaffold and the 3’ 17 
end of the U6 promoter. BsmBI sites added upstream of the 5’sgRNA and 18 
downstream of the 3’-sgRNA were used to seamlessly clone the 5’-sgRNA-sgRNA 19 
scaffold-U6 Promoter-sgRNA-3’ fragment into the vector backbone via golden gate 20 
assembly (10 U BsmBI; 400 U T4 DNA Ligase; 1 mM ATP; 1x NEBuffer 3.1; 0.03 21 
pmol vector backbone; 0.3 pmol insert). Preparation of lentiviral particles and 22 
transduction of HepaRGs were performed based on protocols from addgene. 23 
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Differentiated WT HepaRG or differentiated HepaRG-iCas9-pUSEPR (HepaRG∆IKKβ) 1 
cells were treated with 50 ng/ml of IFN-α and 10 ng/ml of TNFα for 12 h.   2 
Patients population 3 
This study involved a total number of 79 female at the age of 24.7 ± 4 from the East 4 
German anti-D cohort, women infected between 1978 and 1979 by administration of 5 
prophylactic anti-D immunoglobulin contaminated with hepatitis C virus (HCV) 6 
genotype 1b from a single source. All subjects were from limited geographic area in 7 
Germany with similar socioeconomic living conditions. None of these individuals had 8 
any known other risk factors for viral hepatitis or chronic liver disease and were HIV-9 
negative at the time point of sampling (38). This studied comprised 57 with chronic 10 
(HCV RNA positive after repeated examination) and 22 has spontaneously resolved 11 
the HCV infection (HCV RNA negative after repeated examination). Diagnosis of 12 
chronic or resolved HCV infection was determined according to established 13 
guidelines based on standard serological and clinical criteria. The study has been 14 
approved by the research and ethic committee at Bonn University and informed 15 
consent was obtained from the objects prior to inclusion into the study. 16 
Single nucleotide polymorphism Genotyping 17 
Subjects were genotyped using TaqMan SNP Genotyping Assays with TaqMan 18 
Universal Master Mix and QuantStudio™ 6 Flex Real-Time PCR System 19 
(ThermoFisher Scientific). Differences in contingency were assessed Chi-squared 20 
using Prism software (Graphpad Prism version 5.0a). Associations were examined 21 
by the Fisher-exact test implemented in R (version 3.1.1). Allele and genotype 22 
frequencies were analyzed and tested for consistency with Hardy–Weinberg 23 
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equilibrium using a software package designed by Strom and Wienker-TUM 1 
(http://ihg.gsf.de/ihg/snps.html). Genotype frequencies were compared between 2 
individuals with resolved and chronic infection using 2x2 contingency tables. 3 
Statistical analysis  4 
A statistical analysis of the data was performed using Prism software (Graphpad 5 
Prism version 5.0a). The standard error of the mean was calculated from the 6 
average of at least 3 independent samples in a given treatment condition. To 7 
evaluate statistical significance, obtained results were subjected to Student’s t-test 8 
(unpaired, two-tailed test) and a p-value of less than 0.05 was considered significant. 9 
* p ˂ 0.05, **p ˂ 0.01, ***p ˂ 0.001. 10 
 11 
12 
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Results 1 
LCMV-induced hepatocytic NF-kB signaling is required for hepatic virus 2 
control, independent of Kupffer cell-derived factors.  3 
Given the central role of NF-κB signaling in PRR-mediated viral sensing and 4 
activation of innate immunity, we tested whether LCMV infection would activate NF-5 
κB signaling in liver parenchymal cells. To this end, WT mice were intravenously (i.v) 6 
infected with 2x106 PFU of LCMV, and 12 hours post-infection (p.i.), nuclear RelA 7 
translocation was analyzed in livers by immunohistochemistry. Notably, nuclear RelA 8 
translocation was found in hepatocytes and to a lesser degree in KCs of infected 9 
livers (Fig. 1 A). As TNFα is a major driver of nuclear RelA translocation, we first 10 
investigated hepatic TNFα expression. LCMV infection elevated TNFα mRNA in liver 11 
and TNFα protein in serum (Figs. S1 A, upper and lower left panels), which could 12 
be mainly localized to non-parenchymal cells as analyzed by RNA in situ 13 
hybridization (Fig. S1 A, right panel). Further, sequential staining of TNFα by RNA 14 
in situ hybridization with F4/80 demonstrated that the majority of TNFα mRNA 15 
expressing cells are F4/80+ Kupffer cells (Fig. S1 B). To determine whether Kupffer 16 
cells, the major TNFα-producing cell type in the liver or other phagocytosing antigen 17 
presenting cells (APCs) were required for LCMV-induced nuclear RelA translocation 18 
in hepatocytes, mice were treated with clodronate liposomes prior to infection, which 19 
efficiently depleted phagocytic F4/80+ cells in liver (Fig. S1 C). Despite the efficient 20 
depletion of Kupffer cells, efficacy of nuclear RelA translocation in hepatocytes 21 
remain unchanged at 24 h p.i. (Fig. S1 C). Moreover, TNFR1-/- mice displayed 22 
unchanged nuclear RelA translocation upon LCMV infection when compared to WT 23 
livers (Figs. S1 D and S1 E). Consecutive staining of RelA/HNF4α or RelA/F4/80 in 24 
Namineni, et al. 
 
21 
 
livers of TNFR1-/- mice indicated that RelA translocation can be found mainly in 1 
hepatocytes (Fig. S1 F). This suggests that LCMV-induced RelA translocation and 2 
subsequent NF-κB signaling in hepatocytes is not mediated by phagocytic immune 3 
cell populations such as Kupffer cells or cytokines produced by the latter and could 4 
be due to the sensing of LCMV through pathogen recognition receptors (PRRs), 5 
such as TLR3 within hepatocytes (Figs. S1 D and S1 E).  6 
To determine which PRRs were required for LCMV-mediated RelA translocation in 7 
hepatocytes, we infected mice lacking several key viral sensing molecules with 8 
LCMV (Figs. S1 D and E). Hepatocytic RelA translocation was significantly reduced 9 
in livers of Tlr3-/- or Tlr7-/- mice after LCMV infection, indicating that intracellular RNA 10 
sensing by these PRRs is involved. Loss of the adapter protein for RIG-I and MDA5 11 
signaling, MAVS, and a key adapter protein in TLR signaling - MyD88 - also resulted 12 
in a significant reduction in nuclear RelA translocation in hepatocytes post-LCMV 13 
infection. In contrast, nuclear RelA levels remained unchanged in hepatocytes 14 
devoid of STING (Sting-/-), an intracellular DNA sensor, compared to WT (Figs. S1 D 15 
and E)   16 
To elucidate the role of hepatocyte-specific NF-κB signaling in the context of virus 17 
infections, we next analyzed mice with a selective deletion of IKKβ in liver 18 
parenchymal cells (IKKβ∆Hep mice). Specific deletion of IKKβ in liver parenchymal 19 
cells was confirmed via mRNA expression analysis of whole livers, spleens for 20 
control, and isolated hepatocytes from IKKβ∆Hep and WT mice (Fig. S1 G). WT and 21 
IKKβ∆Hep mice were infected i.v. with LCMV and stained for RelA. Nuclear RelA 22 
translocation was observed in hepatocytes from LCMV-infected WT mice with a peak 23 
at 12 hours p.i., whereas IKKβ∆Hep mice infected with the same dose of LCMV-WE 24 
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lacked significant RelA translocation in nuclei of hepatocytes (Fig. 1 B). Of note, 1 
activation of the JNK pathway, analyzed by cJUN phosphorylation and subsequent 2 
nuclear translocation, was lower in IKKβ∆Hep mice compared to WT (Fig. S1 H).  3 
To evaluate the functional consequence of hepatocyte-specific inhibition of canonical 4 
NF-κB signaling, we compared virus titers from the livers of IKKβ∆Hep and WT mice 5 
infected with different doses of LCMV. Strikingly, an approximately 100-fold increase 6 
in virus titers at the peak of infection was found in livers of IKKβ∆Hep mice when 7 
compared to WT mice (Fig. 1 C). Similar virus titers in spleens of IKKβ∆Hep as in WT 8 
mice suggest that peripheral virus control is not dramatically affected (Fig. S1 I).  9 
Furthermore, abundance of CD169+ splenic macrophages was analyzed in WT and 10 
IKKβ∆Hep mice by immunofluorescence and not found to be significantly different 11 
(Fig. S1 J). In addition, flow cytometry of splenic and hepatic immune cells did not 12 
reveal differences in DC maturation between the WT and IKKβ∆Hep mice at day 3 p.i. 13 
(Fig. S1 K).  14 
 15 
LCMV predominantly accumulates in hepatocytes of IKKβ∆Hep livers  16 
To identify the cell types in which LCMV is accumulating and actively replicating over 17 
time, we analyzed the cellular localization of LCMV in frozen liver sections of WT and 18 
IKKβ∆Hep mice post-infection with 2x106 PFU of LCMV at different time points by 19 
staining for LCMV nucleoprotein (NP) (24, 39). While LCMV-WE was localized to 20 
cells exhibiting Kupffer cell-like morphology as early as day 2 p.i., LCMV-WE was 21 
sporadically also detected in hepatocytes by days 6 and 8 p.i. in WT livers, indicating 22 
that LCMV-WE also replicates at very low levels in hepatocytes (Fig. 1 D) contrary to 23 
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earlier findings illustrating Kupffer cells as the only cell type in the liver responsible 1 
for the intake and reduction of liver virus titers (24). Strikingly, hepatocytes from 2 
IKKβ∆Hep mice displayed large clusters filled with LCMV-NP, particularly at days 6 3 
and 8 p.i., due to defective NF-κB signaling in hepatocytes (Fig. 1 D). An 4 
approximate 10-fold increase in LCMV-WE+ hepatic area was found in IKKβ∆Hep 5 
compared to WT livers (Fig. 1 D). Co-stains of LCMV-NP with F4/80+ (Kupffer cells) 6 
or HNF4α+ (hepatocytes) demonstrated that at day 2 p.i., LCMV-NP localized 7 
exclusively in macrophages, whereas at days 6 and 8 p.i., LCMV+ cells in IKKβ∆Hep 8 
livers were mainly hepatocytes, as identified by positive staining for HNF4α (Figs. 1 9 
E and Fig S1 L). Of note, whereas the initial number of LCMV-infected F4/80+ cells 10 
was similar between both genotypes at day 2 p.i., a significantly higher number of 11 
LCMV-infected F4/80+ cells was observed in IKKβ∆Hep than in WT livers at day 8 p.i. 12 
(Fig. 1 E).  13 
 14 
Loss of NF-κB signaling in hepatocytes leads to impaired IFN responses 15 
Considering the critical role of IKKβ in the induction of IFN responses (19, 40, 41), 16 
we investigated whether IKKβ∆Hep livers were defective in the early induction of IFN 17 
responses following LCMV infection. To this end, WT and IKKβ∆Hep mice were 18 
infected with LCMV, and ISG expression was measured over time by qPCR. A 19 
reduction in ISG expression was observed in livers of IKKβ∆Hep compared to WT, 20 
especially at 18 hours and 24 hours p.i. (Fig. 2 A). Among the differentially 21 
expressed ISGs, Mx1, IFIT1, IFIT2, OAS1, OAS3 were significantly reduced in 22 
IKKβ∆Hep mice (Figs. 2 A and S2 A). Furthermore, expression of IFN-dependent 23 
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chemokines such as CXCL9, and CXCL10 important for the chemo-attraction of 1 
immune cells such as monocytes, and T cells were reduced in IKKβ∆Hep livers due to 2 
hepatocyte-specific loss of canonical NF-κB signaling (Fig. 2 A).  3 
As CXCL10 mRNA is abundantly expressed in the liver following IFN induction, it 4 
was used as a marker to monitor antiviral IFN responses following LCMV infection by 5 
sequential CXCL10 RNA in situ hybridization and HNF4α IHC in livers of WT and 6 
IKKβ∆Hep mice (Fig. 2 B). RNA expression of CXCL10 was reduced in hepatocytes 7 
(HNF4α+ cells) of IKKβ∆Hep livers, whereas the non-parenchymal compartment (e.g. 8 
Kupffer cells) still strongly expressed Cxcl10 mRNA (Fig. 2 B). In contrast, in 9 
infected WT livers, both hepatocytes and non-parenchymal cells expressed Cxcl10 10 
mRNA at high levels following infection. This highlights the importance of 11 
hepatocyte-intrinsic canonical NF-κB signaling in amplifying ISGs within hepatocytes 12 
following LCMV infection. Moreover, CXCL10 protein expression was reduced in 13 
IKKβ∆Hep liver compared to WT liver at 18 and 24 hours (Fig. 2 C). We did not 14 
observe a difference in mRNA expression of IFN-α or IFN-β in WT and IKKβ∆Hep 15 
livers, thus the observed differences in ISGs most likely derive from defective IFN 16 
amplification loops in hepatocytes lacking NF-kB signaling (Fig. S2 A). We further 17 
tested this reasoning by intravenously injecting IFN-α into WT and IKKβ∆Hep mice. 18 
Two hours later, mRNA expression of several ISGs was analyzed, which 19 
demonstrated significant reduction in IKKβ∆Hep livers compared to WT, despite 20 
having been exposed to similar amounts of IFN-α (Fig. 2 D). 21 
Signal transducer and activator of transcription 1 (STAT1) is a central transcription 22 
factor which forms heterodimers with STAT2 upon activation by type I and type III 23 
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IFNs. These heterodimers translocate into the nucleus and bind to IFN-stimulated 1 
response elements (ISREs), thereby enhancing ISG expression (42). Strong nuclear 2 
pSTAT1 staining was observed in hepatocytes (red arrow heads in Fig. S2 B) of 3 
LCMV-infected WT livers at 18 hours p.i., which was reduced in IKKβ∆Hep 4 
hepatocytes. In contrast, non-parenchymal cells (black asterisks) were equally 5 
positive for pSTAT1 in both genotypes (Fig. S2 B). Reduction of nuclear pSTAT1 in 6 
hepatocytes is consistent with lower total STAT1 mRNA expression in whole liver 7 
tissue and in hepatocytes of IKKβ∆Hep mice (Figs. 3 A and B). In contrast, neither 8 
STAT2 nor STAT3 phosphorylation (Figs. S2 C and D) were changed in IKKβ∆Hep 9 
livers compared to WT. To elucidate whether the reduction of pSTAT1 was indeed 10 
specific for hepatocytes, consecutive staining of HNF4α-pSTAT1-F4/80 liver sections 11 
derived from WT and IKKβ∆Hep mice 18 hours p.i. was performed. These experiments 12 
and subsequent quantitative analyses indicated that in IKKβ∆Hep livers, pSTAT1 13 
staining is significantly reduced in HNF4α+ hepatocytes, but remained unchanged in 14 
F4/80+ Kupffer cells (Fig. S2 E). Taken together, these experiments indicate that 15 
hepatocyte-specific suppression of canonical NF-κB signaling in IKKβ∆Hep mice leads 16 
to reduced mRNA expression and phosphorylation of STAT1 and STAT1-dependent 17 
ISG induction without affecting pStat1 levels or selected ISGs in non-parenchymal 18 
cells.  19 
 20 
Impaired ISG responses and impaired viral control in IKKβ∆Hep livers are 21 
hepatocyte-intrinsic  22 
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To determine whether increased virus titers and reduced ISG expression in IKKβ∆Hep 1 
livers were caused by an inability of IKKβ∆Hep hepatocytes to integrate paracrine 2 
signaling from other cells (e.g. Kupffer cells) or due to an intrinsic autocrine signaling 3 
defect, hepatocytes isolated from IKKβ∆Hep and WT livers were infected with LCMV 4 
ex vivo (Fig. 3 A). Total cell lysates were analyzed for the expression of viral 5 
transcripts and ISGs. A significant increase in expression of LCMV-NP was observed 6 
in IKKβ∆Hep hepatocytes compared to WT, as well as a decrease in expression of 7 
several ISGs (Fig. 3 B).  8 
The importance of NF-kB signaling in amplifying ISGs was further verified by treating 9 
cultured primary hepatocytes ex vivo with IFN-α. IKKβ-deficient hepatocytes 10 
displayed reduced induction of ISGs compared to WT hepatocytes (Fig. 3 C). 11 
Furthermore, no significant differences were observed in IFN-α and IFN-β mRNA 12 
expression in ex vivo cultivated, LCMV-infected hepatocytes from IKKβ∆Hep and WT 13 
at 18 hours and 24 hours p.i. (Fig. S2 F).Thus, hepatocyte-intrinsic canonical NF-κB 14 
signaling is indispensable for efficient expression of ISGs. 15 
 16 
Hepatic ISGs can be expressed in the absence of hepatic APCs or Kupffer 17 
cells 18 
To further test the interplay between Kupffer cells and hepatocytes in the generation 19 
of hepatic immune responses, mice were treated with clodronate-containing or 20 
empty (PBS) liposomes prior to LCMV infection. Virus titers were measured in livers 21 
of both groups at 1 day p.i. An increase in virus titers from mice with clodronate 22 
depletion was found at 1 day p.i., suggesting that phagocytic immune cells such as 23 
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Kupffer cells are required for optimal control of initial viral replication in hepatocytes. 1 
(Figs. S3 A and B). Despite significant differences in the mRNA expression of Mx1, 2 
OAS2, and OAS3 in the absence of myeloid cells, expression levels of IFN-β and 3 
other ISGs such as ISG15, IFIT1 and CXCL10 were not significantly changed. Thus, 4 
early after infection, several hepatic ISGs can be expressed in the absence of 5 
Kupffer cells or hepatic APCs (Fig. S3 C). 6 
 7 
LCMV accumulates in hepatocytes from mice with defective hepatocyte-8 
specific IFN signaling 9 
Our results so far indicated that defective NF-κB signaling in hepatocytes dampened 10 
IFN responses in liver tissue and facilitated enhanced LCMV replication. To 11 
determine the relative contribution of liver parenchymal- or myeloid-specific IFN 12 
signaling to viral control, mice lacking IFNAR1 receptor selectively in liver 13 
parenchymal cells (IFNAR∆Hep) (20, 26) or myeloid cells, including Kupffer cells 14 
(IFNAR∆Myel) (26, 43) were infected with LCMV. The efficacy and specificity of 15 
IFNAR1 deletion was analyzed in hepatocytes, Kupffer cells or hepatic inflammatory 16 
myeloid cells by PCR. IFNAR was deleted with high efficacy in hepatocytes and 17 
Kupffer cells, but less so in liver-infiltrating monocytes (Fig. S3 D).  18 
Upon infection, LCMV-NP protein expression was analyzed in IFNAR∆Hep, 19 
IFNAR∆Myel, IKKβ∆Hep, and WT livers. Similar to IKKβ∆Hep, livers of IFNAR∆Hep mice 20 
displayed LCMV-positive hepatocyte clusters at day 6 and 8 p.i. (Fig. 4 A), 21 
supporting our hypothesis that a robust early hepatocyte-intrinsic IFN response 22 
(amplified by IKKβ) through IFNAR is required for efficient ISG expression and viral 23 
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control in the liver. Notably, infected IFNAR∆Myel mice displayed impaired protection 1 
against viral replication, as both Kupffer cells and hepatocytes were strongly positive 2 
for LCMV-NP at day 6 p.i. However, the intensity of LCMV-NP expression in 3 
IFNAR∆Myel mice decreased in hepatocytes by day 8 p.i. and was primarily localized 4 
to F4/80+ cells (Figs. 4 A and B), indicating that hepatocytes respond both to 5 
paracrine IFN signaling coming from Kupffer cells and to autocrine IFN signaling 6 
from hepatocytes (Fig. 4 B).  7 
 8 
Hepatocytes are the major producers of ISGs in the liver following LCMV 9 
infection 10 
To further delineate the functional importance of hepatocyte versus myeloid cell-11 
mediated IFN production and IFN responses, whole liver lysates from WT, IKKβ∆Hep, 12 
IFNAR∆Hep, and IFNAR∆Myel mice were analyzed for IFN and ISG expression up to 24 13 
hours after LCMV infection. Overall, IFN-β mRNA expression in livers was 14 
decreased during early phases of LCMV-WE infection (12 hours p.i.) in IFNAR∆Myel 15 
livers compared to IFNAR∆Hep, Ikkβ∆Hep, and WT livers but not at later time points 16 
(Fig. S3 E). This suggests that efficient, early IFN-β expression depends on KCs and 17 
myeloid IFNAR expression. Moreover, early-induced ISGs such as ISG15, Mx1, and 18 
STAT1, as well as IFN-induced chemokines such as CXCL10 were more strongly 19 
upregulated in WT compared to IFNAR∆Hep (strongest reduction), IFNAR∆Myel and 20 
Ikkβ∆Hep livers at 18 hours p.i. (Fig. 4 C). Although ISG expression was decreased in 21 
IFNAR∆Myel compared to WT livers, the expression levels were similar to Ikkβ∆Hep 22 
livers and significantly higher when compared to IFNAR∆Hep (Fig. 4 C).  23 
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Immunohistochemical analyses revealed reduced pSTAT1 signals in hepatocyte 1 
nuclei of LCMV-infected IFNAR∆Hep livers compared to WT at 12 hours and 18 hours 2 
p.i., whereas pSTAT1 in myeloid cells remained unaffected (Fig. 4 D). In contrast, 3 
IFNAR∆Myel livers displayed reduced pSTAT1 in both hepatocytes and myeloid cells 4 
at 12 hours p.i. (Figs. 4 D and S3 F), indicative of a delayed IFN response in 5 
hepatocytes due to impaired IFNAR signaling in myeloid cells. These observations 6 
were confirmed by consecutive staining of HNF4α-pSTAT1-F4/80 in livers of WT and 7 
IFNAR∆Myel mice. Our data indicate that in IFNAR∆Myel mice livers, pSTAT1 staining is 8 
strongly reduced in F4/80+ Kupffer cells, and significantly lowered in HNF4α+ 9 
hepatocytes, in comparison to WT mice (Figs. S2 E and S3 G). Of note, hepatocyte-10 
specific RelA translocation occurred in WT, IFNAR∆Hep, and IFNAR∆Myel with similar 11 
efficacy (Fig. 4 E). This indicates that having an intact NF-kB signaling, hepatocytes 12 
integrate paracrine IFNAR signaling from the neighboring KCs and initiate an 13 
antiviral response at an early stage as well as an intrinsic autocrine IFNAR signaling. 14 
 15 
Depletion of IKKβ in hepatocytes reduces LCMV-induced chemokine 16 
expression and immune cell influx  17 
Efficient activation of IFN signaling in hepatocytes is NF-κB-dependent and is 18 
important for cell-intrinsic control of viral replication and dissemination. IFN 19 
responses also promote cytotoxic CD8+ T-cell responses (44) and may inhibit or 20 
suppress regulatory CD4+ T-cell responses during acute LCMV infections (45). IFN 21 
and NF-κB-driven expression of CXCR3 ligand supports the infiltration of cytotoxic 22 
CD8+ T cells to sites of inflammation, and hepatocytes are a known source of 23 
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CXCR3 ligands such as CXCL9, CXCL10 and CXCL11 during viral infections and 1 
autoimmune disease (46-48). Since we observed an increased viral load in IKKβ∆Hep 2 
compared to WT livers at day 6 and 8 p.i, we investigated whether alterations in 3 
chemokine expression or subsequent intrahepatic immune cell attraction could be 4 
detected.  5 
Real time PCR analysis of LCMV-infected liver homogenates revealed reduced 6 
expression of chemokines such as CCL5, CXCL9, CXCL10 and CXCL11 at 6 and 8 7 
days p.i., but not at 15 days p.i., in IKKβ∆Hep mice compared to WT (Fig. 5 A). To 8 
determine whether intrahepatic recruitment of CD8+ T cells was consequently 9 
affected, we analyzed the abundance of CD8+ T cells in livers of LCMV-infected 10 
IKKβ∆Hep and WT mice via immunohistochemistry. Densitometric analyses of images 11 
indicated significant lower numbers of CD8+ T cells at days 6 and 8 p.i. in livers of 12 
IKKβ∆Hep mice (Fig. 5 B). At 15 and 20 days p.i., no significant differences were 13 
observed in the abundance of CD8+ T cells, highlighting similar CD8+ T cell 14 
recruitment efficacy at later time points in both genotypes (Fig. 5 C). Moreover, 15 
FACS analysis revealed a reduction in the number of LCMV-specific CD8+ T cells at 16 
day 6 p.i. in livers of IKKβ∆Hep mice (Fig. 5 D).  17 
CXCR3 ligands also initiate robust inflammatory cascades by interacting with their 18 
cognate receptor, highly expressed on immune cells such as Kupffer cells, dendritic 19 
cells, neutrophils, natural killer cells and natural killer T cells. Since we identified a 20 
decrease in hepatocyte-derived CXCL10 during both the innate (Fig. 2 A) and 21 
adaptive phases (Fig. 5 A) of the immune response against LCMV infection, we 22 
reasoned that innate immune cell infiltration and activation in livers during the early 23 
and late phases of infection could be affected in IKKβ∆Hep mice. Interestingly, we 24 
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observed reduced mRNA expression of CCL5, CD14, iNOS, CD11b, Ly6C and 1 
CD207 during the early phase of LCMV-WE infection (Fig. S4 A). CCL4, CCR5 and 2 
Ly6C were further reduced in expression during the late phase (Fig. S4 B). 3 
Moreover, we observed a significant reduction in intrahepatic infiltration of CD68+ 4 
monocytes and MHCII+ cells, plausibly due to reduced chemokine expression during 5 
late-stage LCMV-WE infection (Fig. S4 C). Of note, F4/80+ Kupffer cells were not 6 
significantly altered in number in both genotypes (Fig. S4 C). These results were 7 
confirmed by stainings of liver sections using a Kupffer cell-specific marker, Clec4F 8 
(Fig. S4 D). Taken together, these experiments identified a dual role for hepatocyte-9 
specific canonical NF-κB signaling in (1) inducing an adequate cell-intrinsic early, 10 
antiviral response and (2) subsequent viral clearance by attracting adaptive and 11 
innate immune cells to the liver. 12 
 13 
Loss of NF-κB signaling in differentiated HepaRG cells impairs ISG expression 14 
post-treatment with IFN-α or following HBV and HDV infection 15 
We demonstrated that ablation of IKKβ specifically in hepatocytes significantly 16 
impairs an early, efficient viral response to LCMV infection in mouse livers. LCMV 17 
infection has been used as a surrogate model for hepatitis virus infection (49). To 18 
determine whether similar mechanisms operated in human cells infected with distinct 19 
viruses, we utilized differentiated HepaRG cells (dHepaRG) devoid of IKKβ protein 20 
expression (HepaRG-TR-Cas9 IKKβ) generated by CRISPR/Cas9 gene editing or 21 
WT HepaRG cells (Figs. S5 A and B). The requirement for IKKβ in ISG induction 22 
was tested by treating with IFN-α alone or IFN-α/TNFα. Similar to primary murine 23 
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hepatocytes lacking IKKβ (Fig. 3 B), dHepaRG-TR-Cas9 IKKβ displayed significantly 1 
reduced ISG expression compared to Cas9-control dHepaRGs after exposure to 2 
IFN-α (data not shown) or IFN-α/TNFα (Fig. 6 A).  3 
Hepatitis Delta Virus (HDV), a satellite virus of HBV, has been shown to strongly 4 
activate the IFN pathway in hepatocytes (30, 50, 51). We thus analyzed ISG mRNA 5 
expression upon HDV infection in the absence of NF-κB signaling in WT HepaRG 6 
and HepaRG-TR-Cas9 IKKβ. To this end, a pharmacological inhibitor of NF-κB 7 
signaling (ML120B) was used to treat dHepaRG cells before infection with HDV. The 8 
levels of HDV-induced ISGs, such as Viperin, Mx1, OAS1, were decreased in 9 
HepaRGs treated with inhibitor (Fig. 6 B). Expression of the canonical NF-κB target 10 
gene A20, which induces a negative feedback loop to block NF-κB signaling, was 11 
slightly induced by HDV and blocked in the presence of the inhibitor (Fig. 6 B). 12 
Consistent with these findings, HepaRG-TR-Cas9 IKKβ cells infected with HDV 13 
displayed reduced expression of ISGs (Fig. S5 C). Thus, NF-kB signaling appears to 14 
effectively increase the IFN response initiated by HDV in human dHepaRG.  15 
Current knowledge from both experimental and clinical studies suggests that 16 
hepatitis B virus is a weak inducer of innate responses (e.g. IFN and ISGs) and has 17 
evolved strategies to evade sensing (33, 52, 53). Thus, replication of HBV can be 18 
controlled by adding exogenous IFN-α. We therefore tested whether the inhibitory 19 
action of IFN-α on HBV would be dampened in the absence of NF-κB signaling. To 20 
this end, a pharmacological inhibitor of NF-κB signaling was used to treat HBV-21 
infected dHepaRGs. First, dHepaRGs were treated with IKKβ Inhibitor or control 22 
(DMSO) followed by IFN-α treatment alone. It has been shown that type I IFN 23 
signaling activates NF-κB signaling in various human and murine cell types (54). 24 
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Consistently, IFN-α-induced RelA phosphorylation was reduced in the presence of 1 
the NF-κB inhibitor, as verified by Western blot analysis of protein lysates from 2 
inhibitor or mock-treated HepaRGs (Fig. S5 D). Next, IKKβ inhibitor or untreated 3 
dHepaRGs were infected with HBV and then treated with IFN-α (Fig. 6 C). IKKβ 4 
inhibition effectively dampened IFN-α-mediated suppression of HBV DNA, RNA, as 5 
well as HBV antigens (HBsAg, HBeAg) (Fig. S5 E). Expression of ISGs such as 6 
Mx1, OAS1, and ISG15, required for controlling HBV replication, were decreased in 7 
HBV + IFN-α-treated HepaRGs in the presence of the IKKβ inhibitor (Fig. 6 D). 8 
Moreover, expression of the canonical NF-κB target gene, A20, was also reduced 9 
(Fig. 6 D). Thus, intact NF-kB signaling appears to be required for optimal 10 
effectiveness of IFN-α treatment against HBV infection. 11 
To further decipher the role of NF-κB in the response to viral infection in patients, we 12 
analysed the polymorphism of NF-κB 1 in the serum of patients chronically infected 13 
with HCV or of patients who have resolved HCV infection (Fig. S6). To decipher role 14 
of NF-κB in HCV infection, we analysed 6 specific NF-κB 1 single nucleotides 15 
polymorphisms (SNPs) – including the homozygote (SNP+/+), heterozygote (SNP+/-) 16 
SNP state as well as the loss of SNP (SNPwt/wt) in a cohort of approximately 80 17 
patients. Three different groups of NF-κB 1 SNPs were identified (Fig. S6): (1) SNPs 18 
that are not significantly differentially represented between chronic HCV carriers and 19 
resolvers (SNP4 and SNP5); (2) Homozygote SNPs (SNP+/+) (SNP1 and SNP2) 20 
that are significantly increased in chronic HCV carriers versus HCV resolvers; (3) 21 
SNPwt/wt (SNP3 and SNP6) which are significantly increased in chronic HCV 22 
carriers versus HCV resolvers. Altogether, these results indicate that SNPs in NF-κB 23 
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are correlated with clearance or chronic infection of HCV and thus may play a role in 1 
the resolution of HCV infection. 2 
3 
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Discussion  1 
While hepatocytes are known to execute metabolic functions in the liver, their role in 2 
anti-bacterial innate immunity has been well established, including expression of 3 
antibacterial proteins like complement proteins, opsonins and fibrinogen (7, 55). 4 
Hepatic viral infections, such as HBV and HCV lead to chronic hepatitis, cirrhosis 5 
and hepatocellular carcinoma, causing millions of deaths worldwide (3). During such 6 
chronic viral infections, innate sensing mechanisms are antagonized by viral proteins 7 
within infected hepatocytes which would otherwise control the virus which implicates 8 
functional antiviral mechanisms within the cells. Work focused delineating the 9 
involvement of liver cell types in clearing viral infections identified KCs as the 10 
principle cell type for virus control through IFN-mediated anti-viral signaling (3). 11 
Considering that the major molecular signaling pathways involved in viral control 12 
within hepatocytes are similar to those in immune cells, we hypothesized that 13 
hepatocyte-derived innate immune signalling might play a central role in controlling 14 
hepatic viral infections. 15 
Here, we show that hepatocyte-specific NF-κB activation is essential for a timely and 16 
efficient hepatic viral control. Loss of NF-κB signaling in hepatocytes resulted in a 17 
delay of the early IFN response and, consequently, in a 100-fold virus titer increase 18 
in an LCMV-WE infection model. Of particular note, this blockade of NF-κB signaling 19 
in hepatocytes was sufficient to enhance virus replication despite the presence of 20 
intact overall hepatic IFN-α signaling in hepatocytes and fully functional Kupffer cells. 21 
The absence of LCMV in KCs from WT livers and its presence in KCs from IKKβ∆Hep 22 
livers at day 8 p.i. - at a time point at which a robust adaptive immune response is 23 
activated - suggests that Kupffer cell-derived signaling alone (IFN, NF-κB) does not 24 
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suffice to suppress viral growth in the liver when NF-κB signaling is inhibited in 1 
hepatocytes.    2 
Initially, we considered the possibility that Kupffer cell- or other APC-derived signals 3 
might be required for LCMV-induced nuclear RelA translocation in hepatocytes, 4 
since Kupffer cells are known to be major producers of molecules that stimulate NF-5 
kB signaling, including TNFα. However, nuclear RelA translocation in hepatocytes 6 
after LCMV-WE infection persisted even when Kupffer cells were depleted or when 7 
TNFR1 was knocked out. This indicated that nuclear RelA translocation was 8 
independent of molecular cues/cytokines derived from Kupffer cells/APCs, the TNF-9 
TNFR1-axis and could be a result of direct sensing of LCMV by PRRs within the 10 
hepatocytes, as highlighted by the decrease of RelA translocation upon TLR3, TLR7, 11 
MyD88, or MAVS knock down. For control, Sting-/- mice, did not display a decrease 12 
in RelA translocation.    13 
Mice with hepatocyte-specific deletion of IKKβ (IKKβ∆Hep) and consequently defective 14 
RelA translocation showed increased virus replication and delayed virus clearance. 15 
Thus, induction of RelA in hepatocytes contributes to efficient virus control in liver. 16 
Notably, in livers of IKKβ∆Hep mice, IFN-induced mRNA expression of ISGs and 17 
consequent phosphorylation of STAT1 was found to be delayed and reduced in the 18 
hepatocytic compartment, whereas it was still immuno-positive in the non-19 
parenchymal cell compartment compared to the livers of WT mice in which both 20 
hepatocytes and non-parenchymal cells exhibited equal levels of pSTAT1. 21 
Interestingly, this happened in the context of unchanged IFN-α/IFN-β expression 22 
levels in IKKβ∆Hep mice. We next found that livers depleted of KCs by clodronate also 23 
expressed IFN-β levels similar to WT, whereas some ISGs were expressed at lower 24 
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levels in clodronate-treated livers. The residual IFN-β expression in KC-depleted 1 
livers could plausibly be derived from other immune cells. Our experiments indicated 2 
that myeloid cells expressing IFNAR are important for inducing the early expression 3 
of ISGs and hepatocytic pSTAT1. Interestingly, reduced IFN-β expression and a 4 
delay in pSTAT1 translocation in hepatocytes in IFNAR∆Myel livers indicate that 5 
hepatocytes might require initial IFN cues from KCs. Accordingly, during the effector 6 
phase of infection at day 6 p.i., there was a massive accumulation of LCMV in both 7 
KCs and hepatocytes in IFNAR∆Myel livers. Remarkably, by day 8 p.i. there was a 8 
strong decrease in the number of infected hepatocytes, whereas LCMV levels in 9 
myeloid cells remained high. This indicated that hepatocyte-specific ISG expression 10 
and viral control within hepatocytes, eventually occurred despite the lack of IFN 11 
signaling or viral control in KCs - either due to autocrine antiviral signaling within 12 
hepatocytes and/or paracrine signals from other cells (e.g. pDCs).  13 
In addition, our work underlines that the hepatic increase of LCMV found in IKKβ∆Hep 14 
mice is independent of LCMV-induced splenic responses, as similar levels of splenic 15 
CD169+ macrophages and splenic DC maturation were found in WT and IKKβ∆Hep 16 
mice. This finding highlights that the increased viral replication in IKKβ∆Hep livers is a 17 
causal effect of a diminished hepatocyte intrinsic innate immune response. 18 
It is well established that canonical NF-κB subunits (p50:p65) are part of an 19 
enhanceosome complex along with ATF-2/c-Jun, IRF-3/IRF-7 that activates 20 
Interferon-β gene expression. Also, it is known that NF-κB activation is required for 21 
the induction of pro-inflammatory cytokines, as well as early expression of IFN-β 22 
during RNA virus infection and to maintain a basal level of IFN and interferon-23 
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inducible genes (56-59). Since NF-κB and antiviral signaling mechanisms exist in 1 
hepatocytes which constitute approximately 80% of the entire liver mass, we 2 
hypothesized that defective NF-κB within hepatocytes would blunt the overall 3 
antiviral response in the liver. Consistent with this hypothesis, we could successfully 4 
demonstrate a direct link between the requirement of hepatocyte-intrinsic NF-κB 5 
signaling and IFN-α responses by treating hepatocytes lacking IKKβ with IFN-α 6 
directly in vitro and in vivo. In both cases, ISG expression was decreased 7 
significantly in the absence of IKKβ. We could also corroborate these observations in 8 
HDV infection models or with IFN-α + TNFα treatment of dHepaRGs, where we saw 9 
blunted expression of ISGs in dHepaRGs lacking NF-kB signaling (57, 58). 10 
Consistent with our data, mice with hepatocyte-specific deletion of IFNAR displayed 11 
strongly reduced ISG expression and strongly increased LCMV in hepatocytes as 12 
early as 6 days p.i. Thus, presence of both IFNAR and NF-κB signaling in 13 
hepatocytes is needed to execute optimal and timely ISG responses and control 14 
hepatic viral LCMV-infection - with IKKβ and NF-kB signaling serving as amplifiers of 15 
IFNAR signaling. Moreover, these data point to hepatocytes being an important 16 
producer of ISGs through IFNAR signaling.    17 
Of note, expression of IFN-induced chemokines such as CXCL9, CXCL10 and 18 
CXCL11, important for the attraction of monocytes and other immune cells (60-62), 19 
were also reduced in the livers of IKKβ∆Hep mice compared to WT. This decrease 20 
was accompanied by a reduction in the number of effector CD8+ T cells in IKKβ∆Hep 21 
livers at early time points (day 6 and 8 p.i.) following LCMV infection. Notably, once 22 
LCMV infection has been controlled in both models at late time points (later 23 
than/around 15 days p.i.), no differences in hepatic CD8+ T cell numbers could be 24 
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detected. We also saw a reduction in the intrahepatic influx of innate immune cells in 1 
IKKβ∆Hep mice. Thus, in addition to impaired hepatocyte-intrinsic viral control, loss of 2 
NF-kB signaling in hepatocytes also prevents the liver from mounting an optimal 3 
innate and adaptive immune response, which may further promote viral 4 
accumulation and may at least partially account for the observed increase in the 5 
number of LCMV-positive Kupffer cells identified in IKKβ∆Hep livers in the current 6 
study (63, 64). However, at later time points (between days 8 and 20 p.i.), LCMV-WE 7 
infection was controlled - even in the absence of NF-κB signaling in hepatocytes.  8 
LCMV-WE can infect and replicate in both Kupffer cells and hepatocytes, triggering 9 
potent innate and adaptive immune responses. In the case of Kupffer cell infection –10 
innate immune responses can support viral elimination, although with a delay - even 11 
in the absence of hepatocytic NF-κB. However, other hepatic viruses’ which 12 
specifically target hepatocytes, such as HBV or HDV, might not trigger immune 13 
responses in Kupffer cells in the absence of NF-κB signaling in hepatocytes, 14 
preventing the elimination of the infection.  15 
Recently, a correlation was indeed demonstrated  between NF-κB single nucleotide 16 
polymorphism and susceptibility to HCV infection in different Chinese populations, 17 
highlighting a role of NF-κB in the control of hepatic viral infection (65, 66).  18 
We analyzed the expression of 6 SNP of NF-κB 1 in the serum of approximately 80 19 
HCV chronically infected or resolved patients. These results confirmed the previously 20 
published data (65, 66), emphasizing a possible role of NF-κB in the activation of 21 
innate immune responses (such as IFN production and signalling) and in the 22 
control/resolution of hepatic viral infection. 23 
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Moreover, we showed that NF-kB signaling is required for viral control in hepatocytes 1 
in human cells (dHepaRG) and for another virus (HDV). HBV usually does not 2 
induce strong IFN responses (67). Thus, administration of IFN-α is common 3 
therapeutic strategy for the treatment of this disease. In the current study, we 4 
demonstrated that NF-kB signaling is required for the therapeutic effects of IFN-α 5 
treatment in the context of an HBV infection. Thus, NF-kB signaling in hepatocytes 6 
may play a broad role in the pathogenesis of liver viral infections, as well as the 7 
molecular mechanisms underlying the efficacy of some anti-viral therapies.  8 
In summary, we conclude that infected hepatocytes in the liver actively sense viral 9 
replication and initiate/incorporate autocrine and paracrine IFN signaling cascades 10 
and contribute to the overall production of cytokines, chemokines and ISGs. When 11 
NF-κB signaling is impaired in hepatocytes, ISGs responses in the liver becomes 12 
markedly delayed and reduced, virus accumulates within hepatocytes, and the 13 
usually well-orchestrated adaptive immune responses during the effector phase of 14 
the infection are less effective and delayed. Thus, we propose a model of hepatic 15 
LCMV infection that can be divided in distinct phases: In the first “wave”, LCMV 16 
infects macrophages, which is associated with a strong innate immune response in 17 
these cells (e.g. TNFα). This first wave primes the upcoming wave through the 18 
secretion of IFNs, inducing the first ISGs within the liver (e.g. in Kupffer cells and 19 
other innate immune cells). In the second “wave”, LCMV is sensed by hepatocytes, 20 
preventing the establishment of the virus in cells with functional NF-κB signaling and 21 
potent PRR responses. Taken together, our results highlight the previously 22 
unrecognized role played by hepatocyte-derived NF-κB in supporting IFN-mediated 23 
immune responses and early resistance to hepatic viral infections. 24 
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Figure legends 1 
Figure 1. LCMV-induced hepatocytic NF-kB signaling is required for overall 2 
hepatic virus control independent of Kupffer cell derived factors. (A) C57BL/6 3 
(WT) mice were intravenously (i.v.) infected with 2x106 PFU of LCMV-WE. 24 h post 4 
infection (p.i.), livers were harvested and frozen sections were stained for RelA 5 
(green), mainly localized in nuclei of hepatocytes (DAPI; blue; n=4). Kupffer cells 6 
(red) were stained using an anti-F4/80 antibody. RelA+ Hepatocytes are indicated by 7 
white arrow heads.  RelA+ KCs are denoted by white asterisks. (B) C57BL/6 and 8 
IKKβ∆Hep mice were infected i.v. with 2x106 PFU of LCMV-WE (n=3). Livers were 9 
isolated starting from 3 h until 24 h p.i and frozen liver sections of infected mice were 10 
stained for RelA (green) and DAPI (blue) to stain nuclei. Representative images from 11 
12 h p.i. are shown. Livers of uninfected WT mice were used as controls. Percentage 12 
of RelA+ area is quantified (right panel). (C) WT and IKKβ∆Hep mice were i.v. infected 13 
with 1x105 PFU or 2x105 PFU of LCMV-WE (n=3-4 for each time point). Hrs = Hours. 14 
Livers from infected mice were harvested at indicated time points and analyzed for 15 
infectious virus using a virus plaque forming assay (n=3-5 per liver tissue sample). 16 
Virus titers were normalized to mg of liver tissue. (D) (E) WT and IKKβ∆Hep mice were 17 
infected i.v. with 2x106 PFU of LCMV-WE (n=4). Livers were isolated at different time 18 
points post infection. Frozen liver sections from infected mice were stained for 19 
LCMV-NP (green) and F4/80 (red). Co-localization signal is indicated in yellow. 20 
Representative images from indicated time points are shown. Yellow asterisks 21 
indicate non-parenchymal liver cells (e.g. Kupffer cells) positive for LCMV-NP.  Error 22 
bars indicate mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; unpaired Student’s t-23 
test. 24 
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Figure 2. Loss of NF-κB signaling in hepatocytes leads to impaired interferon 1 
responses. WT, and IKKβ∆Hep, mice were i.v. infected with 2x106 PFU of LCMV-WE 2 
and a time course was performed from 0 – 24 h (n=3-4 per each time point). (A) 3 
Livers were isolated at indicated time points and analyzed for ISG expression 4 
through qRT-PCR. (B) Cxcl10 (IP10) mRNA expression from LCMV-WE infected 5 
livers analyzed by in situ hybridization and HNF4α staining was performed on 6 
consecutive slides. Red triangle: hepatocytes. Black asterisks: non-parenchymal 7 
cells (e.g. Kupffer cells). (C) CXCL10 protein was analyzed by ELISA on total liver 8 
extract and is presented as average quantity of CXCL10 per µg of total protein. (D) 9 
WT and IKKβ∆Hep mice were given 500 U of IFN-α i.v. (n=3), compared to untreated 10 
WT livers and tested for the expression of ISGs through qRT-PCR. Error bars 11 
indicate mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; unpaired Student’s t-test.  12 
Figure 3. Impaired ISG responses and viral control in IKKβ∆Hep livers is 13 
hepatocyte-intrinsic. (A) Schematic model describing the experiment. Hepatocytes 14 
were isolated from livers of WT and IKKβ∆Hep mice and infected ex vivo with LCMV-15 
WE (MOI=1). (B) RNA was extracted at the indicated time points from isolated 16 
hepatocytes and analyzed for LCMV nuclear protein (NP), glycoprotein (GP) and 17 
ISG expression. (C) Hepatocytes were isolated from WT and IKKβ∆Hep mice and 18 
treated ex vivo with 250 U of IFN-α. RNA was extracted from hepatocytes at 12h 19 
post treatment and analyzed for the expression of ISGs. Error bars indicate mean ± 20 
SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; unpaired Student’s t-test. 21 
Figure 4. LCMV accumulates in hepatocytes from mice with defective 22 
hepatocyte-specific interferon signaling. WT, IKKβ∆Hep, IFNAR∆Hep and 23 
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IFNAR∆Myel mice were i.v. infected with 2x106 PFU of LCMV-WE and tested for the 1 
distribution of LCMV-NP expression (n=3-4, each time point). (A) Livers were 2 
isolated at the indicated time points, and stained for LCMV-NP. Representative 3 
images are shown. White asterisks: non-parenchymal liver cells LCMV-NP+. White 4 
arrow heads: hepatocytes LCMV-NP+. (B) Livers of infected mice of the indicated 5 
genotypes were stained with F4/80 (red), LCMV-NP (green), DAPI (blue). White 6 
arrow heads: hepatocytes. Yellow asterisks: Kupffer cells. (C) Livers were isolated at 7 
indicated time points and analyzed for ISG expression through qRT-PCR. (D, E) 8 
Histological analysis of the indicated genotypes for nuclear translocation of pSTAT1 9 
or RelA at 12 h and 18 h p.i. Red arrow heads: hepatocytes. Black asterisks: non-10 
parenchymal liver cells. Error bars indicate mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 11 
0.001; unpaired Student’s t-test. 12 
Figure 5. Depletion of IKKβ in hepatocytes reduces hepatic immune cell influx 13 
and adaptive immune responses. 14 
WT and IKKβ∆Hep mice were infected i.v. with 2x106 PFU of LCMV-WE (n=6 each 15 
time point) and analyzed. (A) Livers were analyzed for the expression of selected 16 
chemokines by qRT-PCR. (B) Frozen liver sections were stained for CD8+ T cells 17 
(red), LCMV-NP (green), and F4/80 (blue). (C) Paraffin-embed liver sections were 18 
stained by IHC for CD8+ T cells. (B, C) Representative images from indicated time 19 
points are shown. Total CD8+ area was densitometrically quantified for each 20 
genotype. (D) Flow cytometry analysis of IFN-γ+ CD8+ T cells isolated from the livers 21 
of LCMV infected WT and IKKβ∆Hep mice 6 days p.i. and stimulated with LCMV gp33 22 
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peptide or control peptide (n = 6 each genotype). Error bars indicate mean ± SEM, *p 1 
≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; unpaired Student’s t-test.  2 
Figure 6. HepaRG cells devoid of canonical NF-κB signaling exhibit reduced 3 
expression of ISGs. 4 
(A) HepaRGs lacking IKKβ (HepaRG-TR-Cas9 IKKβ) and control HepaRGs 5 
(HepaRG-TR-Cas9 CTRL) were treated for 2 h with a combination of IFN-α (50 U/ml) 6 
and TNF-α (10ng/ml). Expression profile of indicated ISGs measured by qRT-PCR. 7 
(B) dHepaRG were treated or not for 12 h with IKK2 Inhibitor (ML120B; 10 nM) and 8 
further infected with HDV and lysed 6 days later. qRT-PCR was performed with 9 
specific primers as indicated and normalized to the housekeeping gene, PRNP. (C) 10 
Schematic drawing of the performed experiment in Figure D. HepaRGs were 11 
infected with HBV. After 6 days, cells were treated with TPCA1 (10 nM). After 1 day 12 
of treatment, IFN-α (50 U/ml) was added to the medium up until day 13 p.i. (D) Total 13 
DNA and total RNA were extracted from dHepaRG. qRT-PCR was performed to 14 
verify the expression of ISGs. Error bars indicate mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, 15 
***p ≤ 0.001; unpaired Student’s t-test. 16 
17 
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Graphical Summary – A dual role for hepatocyte intrinsic canonical NF-κB 1 
signaling in virus control. 2 
(Innate sensing) LCMV is sensed leading to RelA activation and nuclear 3 
translocation within hepatocytes through TLR3, TLR7, MyD88 and MAVS-dependent 4 
mechanisms and independent of TNF, TNFR1, KCs or other APCs. (ISG 5 
expression/ innate immunity) Lack of IKKβ in hepatocytes leads to a reduced ISG 6 
response (e.g. upon LCMV infection in vitro) and a major reduction in the overall 7 
hepatic ISG production (e.g. upon LCMV infection in vivo), indicating that 8 
hepatocytes are the major producers of ISGs in the liver. In line, lack of IFNAR in 9 
hepatocytes leads to the strongest reduction of ISGs in total liver tissue upon LCMV 10 
infection. Still, Kupffer cell-derived IFNAR responses are important to support the 11 
timely and effective ISG production by hepatocytes. (Adaptive Immunity) During the 12 
onset of an adaptive immune response in the effector phase, IKKβ∆Hep livers display 13 
decreased cytokine and chemokine expression as well as a decrease in the 14 
infiltration of LCMV-specific CD8+ T cells leading to an increased and uncontrolled 15 
virus replication in the livers. (Virus control – effector phase) Hepatocytes lacking 16 
IKKβ and IFNAR display similar response to LCMV infection wherein virus 17 
accumulated in the hepatocytes as clusters. Hepatocytes from IFNAR∆Myel livers 18 
integrate paracrine cues from neighboring KCs and control viral replication while KCs 19 
cannot control viral replication.  20 
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